Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess if comparable rates of the composite efficacy failure (biopsy-proven acute rejection of ISHLT grade ≥ 3A, acute rejection episodes associated with hemodynamic compromise, graft loss/re-transplant, death, or loss to follow-up) are achieved in cohorts of de novo heart recipients treated with Certican-reduced Neoral versus MMF-Neoral standard dose at 12 months after initial dose of study medication
Critère d'inclusion
- de novo heart transplantation